Checkpoint Therapeutics (NASDAQ:CKPT) Price Target Raised to $7.00

Checkpoint Therapeutics (NASDAQ:CKPT) had its target price upped by Lake Street Capital from $4.00 to $7.00 in a research note released on Monday morning,Benzinga reports. Lake Street Capital currently has a buy rating on the stock.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $20.00 target price on shares of Checkpoint Therapeutics in a research report on Monday.

Checkpoint Therapeutics Trading Down 3.8 %

CKPT stock opened at $3.57 on Monday. The firm has a 50-day moving average of $3.55 and a two-hundred day moving average of $2.69. Checkpoint Therapeutics has a 12 month low of $1.38 and a 12 month high of $4.50. The company has a market cap of $174.33 million, a price-to-earnings ratio of -1.94 and a beta of 1.34.

Checkpoint Therapeutics (NASDAQ:CKPT) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.23) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.08). As a group, equities analysts forecast that Checkpoint Therapeutics will post -0.91 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in CKPT. Virtu Financial LLC acquired a new stake in shares of Checkpoint Therapeutics in the third quarter valued at $30,000. XTX Topco Ltd purchased a new position in Checkpoint Therapeutics during the 2nd quarter valued at about $34,000. Gladstone Institutional Advisory LLC grew its position in Checkpoint Therapeutics by 141.4% in the 3rd quarter. Gladstone Institutional Advisory LLC now owns 35,000 shares of the company’s stock valued at $78,000 after acquiring an additional 20,500 shares in the last quarter. Magnus Financial Group LLC increased its stake in Checkpoint Therapeutics by 12.9% during the third quarter. Magnus Financial Group LLC now owns 35,000 shares of the company’s stock worth $78,000 after purchasing an additional 4,000 shares during the period. Finally, Choreo LLC lifted its position in shares of Checkpoint Therapeutics by 12.2% during the second quarter. Choreo LLC now owns 65,002 shares of the company’s stock worth $133,000 after purchasing an additional 7,080 shares in the last quarter. 22.00% of the stock is currently owned by institutional investors and hedge funds.

Checkpoint Therapeutics Company Profile

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.